{"entity":{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","aka":["MIZAR-003"],"tldr":"A phase 2 trial of GC101 TIL, Dacarbazine, Temozolomide in melanoma, run by Shanghai Juncell Therapeutics, now recruiting.","summary":"A Study of GC101 TIL in Advanced Melanoma is a phase 2 interventional study registered as NCT06703398 by Shanghai Juncell Therapeutics, with 98 participants planned, started 2024-12-20 and due to reach its primary completion in 2026-05-12. Interventions recorded: GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06703398","url":"https://clinicaltrials.gov/study/NCT06703398"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["gc101-til","dacarbazine","temozolomide","paclitaxel"],"companies":["shanghai-juncell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06703398","phase":"2","setting":"A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma","sponsor":"Shanghai Juncell Therapeutics","participation":[{"nct":"NCT06703398","source":"https://clinicaltrials.gov/study/NCT06703398","fetchedAt":"2026-10-07T16:54:56.691Z","studySha256":"487c41b860d3982674f7c1456b0ef3f14e1502db3664d69fac49353234558ff1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-05","leadSponsor":"Shanghai Juncell Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":98,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-12-20","startedType":"actual","enrolled":98,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06703398/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/"}]}}